BioNTech’s $1 Billion Buyback Meets a Market That Still Needs Convincing

BioNTech launches $1B share repurchase program, underscoring strong cash position, but stock near lows as oncology pipeline faces scrutiny.

BioNTech has launched a share repurchase programme of up to $1 billion, a move that underscores the company’s formidable cash position even as its stock languishes near multi-month lows. The timing is telling: the buyback arrived on the same day the stock slipped 2.41% to €74.80, highlighting the chasm between BioNTech’s financial heft and the market’s persistent doubts about its post-Covid future.

The programme runs through 6 May 2027 and covers American Depositary Shares traded on the Nasdaq Global Select Market. It has been structured to comply with both European market-abuse rules and US regulations, with an independent credit institution making all trading decisions. The repurchased shares are earmarked for ordinary business obligations, including employee incentive schemes. BioNTech stressed that the timing and size of each buyback will depend on market conditions, giving the company flexibility to act when it sees value.

That value is easy to find in the numbers. BioNTech ended the first quarter with €16.76 billion in cash, money-market instruments and securities. The buyback consumes less than 6% of that war chest. But the stock trades roughly 29% below its 52-week high of €105.80 and well under its 200-day moving average of €85.88. Year-to-date the shares have lost about 8%, and over the past twelve months the decline stands at nearly 22%.

The underlying financial picture explains the caution. First-quarter 2026 revenue came in at €118.1 million, down from €182.8 million a year earlier, as Covid vaccine sales continued to fade. The net loss widened to €531.9 million, driven by a jump in research spending to €557.0 million, most of it directed at oncology programmes and antibody-drug conjugates. BioNTech still expects full-year revenue of €2.0 billion to €2.3 billion and adjusted R&D costs of €2.2 billion to €2.5 billion.

Against that backdrop, the most important catalyst this week came not from the buyback but from the ASCO conference in Chicago, where BioNTech and partner Bristol Myers Squibb presented interim data on Pumitamig, their bispecific antibody for lung cancer. The ROSETTA-Lung-02 study showed encouraging anti-tumor activity when the drug was combined with chemotherapy. BioNTech is now testing Pumitamig in other solid tumours, suggesting the asset has moved beyond early-stage speculation into a full-blown global development programme.

Still, the market is not rushing to celebrate. BioNTech and BMS modified the trial design to make progression-free survival the sole primary endpoint. Overall survival remains part of the analysis but is no longer co-primary, a shift that some physicians and regulators view as a softer yardstick. Investors also know that no oncology-related revenue is expected in 2026. The stock’s RSI of 38 points to persistent selling pressure, not panic, but it leaves little room for doubt about the prevailing mood.

The buyback offers a partial remedy. It improves capital efficiency and signals management’s confidence in the company’s intrinsic value. But it does nothing to answer the central question: when will the pipeline generate commercial returns? Analysts currently see a consensus target of around €107, implying a 43% upside from current levels. That gap is not a guarantee — it illustrates the disconnect between near-term skepticism and longer-term potential.

BioNTech’s challenge is to convince the market that its oncology pivot is real and that Pumitamig can succeed in a crowded field. The ASCO data gives the bears a reason to pause, but concrete answers are unlikely before the next pipeline update in the autumn. Until then, the buyback puts a floor under the stock while the story itself remains a work in progress.